Adding the androgen receptor inhibitor darolutamide (Nubeqa, Bayer/Orion) to androgen deprivation therapy (ADT) and chemotherapy prolongs the survival of men with metastatic hormone-sensitive prostate cancer (mHSPC), results from a new trial show.
Data from the global randomized, phase 3 ARASENS trial demonstrate that patients assigned to darolutamide plus ADT and docetaxel had a 32.5% lower risk for death compared with men assigned to placebo plus ADT and docetaxel. The reduction corresponds to
APRIL 12, 2022